as 05-30-2025 4:00pm EST
Stocks
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Founded: | 2018 | Country: | United States |
Employees: | N/A | City: | DURHAM |
Market Cap: | 60.9M | IPO Year: | N/A |
Target Price: | $7.00 | AVG Volume (30 days): | 151.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.02 | EPS Growth: | N/A |
52 Week Low/High: | $0.65 - $2.18 | Next Earning Date: | 05-15-2025 |
Revenue: | $13,651,000 | Revenue Growth: | -28.19% |
Revenue Growth (this year): | 22% | Revenue Growth (next year): | 100.89% |
IRD Breaking Stock News: Dive into IRD Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
Simply Wall St.
15 days ago
GlobeNewswire
17 days ago
GlobeNewswire
20 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "IRD OPUS GENETICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.